BioLife Solutions Inc (BLFS): Price Target Chart

Symbol and logo of brand BioLife Corp (BLFS)

BioLife Solutions, Inc. (BLFS) serves as a key ally for gene therapy developers by supplying specialized tools and equipment. This price chart illustrates the asset's dynamics, with the current indicator standing at 30.85. The business relies on the cryopreservation of biomaterials for the B2B regenerative medicine segment. Growth is driven by current demand for consumables, although the market has already priced in the impact of non-core asset sales, and the automation of hubs is only beginning to take shape.

BioLife Solutions (BLFS) - Price Target Chart from 07/04/2022 to 10/18/2026
Manufactured products of biolifesolutions.com

The market valuation for BioLife Solutions, Inc. (BLFS) is based on the average target prices provided by professional analysts. This market consensus aggregates expert expectations to establish the asset's fair value. The indicator's trend reflects revised forecasts as margins scale within the biomaterials segment. The increase in the target price confirms the effectiveness of the company's operating leverage. Investors should utilize trend inflection points to identify entry levels without overpaying.

Competing companies

Price Target Chart TEM (tempus.com)|Price Target Chart Qiagen QGEN|Ionis Pharmaceuticals, Inc. - Price Target Chart|Repligen Corp. - Analyst Consensus Forecast|Forecast Levels Chart RNA|CRISPR Therapeutics AG (CRSP) - Price Target Chart|WGS - Analyst Median Target|RARE (Ultragenyx) - Analyst Consensus Forecast|Broker Consensus Forecast BEAM (Beam Therapeutics Inc)|Price Target Chart Sarepta Therapeutics Inc (SRPT)|Twist Bioscience Corp - Broker Consensus Forecast|Analyst Consensus Forecast TXG (10x Genomics, Inc.)|Analyst Consensus Forecast intelliatx.com NTLA|Stoke Therapeutics, Inc. - Analyst Consensus Forecast|WVE: Price Target Chart|MAZE: Analyst Consensus Forecast|SION - Analyst Median Target|Price Target Chart Prime Medicine, Inc.|Average Forecast Price tayshagtx.com TSHA|Price Target Chart uniQure (QURE)|Price Target Chart MGTX (MeiraGTx Holdings)|Analyst Consensus Forecast RGNX (Regenxbio)|Analyst Median Target Solid Corp (SLDB)|Ocugen, Inc. - Analyst Consensus Forecast|Forecast Levels Chart PACB|BNTC: Analyst Consensus Forecast|Average Forecast Price Design Therapeutics Inc (DSGN)|Consensus Target RCKT|FDMT: Fair Value Consensus|Price Target Chart Lexeo Therapeutics (LXEO)|Analyst Median Target korrobio.com|Price Target Chart Editas Medicine EDIT|Silence Therapeutics PLC (SLN) - Average Forecast Price|PRQR - Price Target Chart|CDXS: Price Target Chart|SGMO (Sangamo Therapeutics) - Consensus Target|Nautilus Bio (NAUT) - Analyst Consensus Forecast|Consensus Target MGX|DTIL (Precision BioSciences Inc.) - Analyst Forecast Prices|Analyst Consensus Forecast GBIO|Analyst Median Target Boundless Bio Inc|Price Target Chart Exicure XCUR|Imunon Inc (IMNN) - Average Forecast Price|PHIO - Price Target Chart|MBIO (Mustang Bio, Inc.) - Broker Consensus Forecast|transcodetherapeutics.com (RNAZ) - Price Target Chart|BNGO - Analyst Median Target|Consensus Target APDN|BLUE: Fair Value Consensus|Analyst Consensus Forecast IPA|Analyst Median Target Omega Therapeutics Inc|Price Target Chart Singular Genomics Systems Inc OMIC|RGLS: Broker Consensus Forecast|Syros Pharmaceuticals - Analyst Consensus Forecast|telesisbio.com (TBIO) - Consensus Target|TCON (TRACON Pharmaceuticals, Inc.) - Consensus Target|UBX - Analyst Median Target